A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors

被引：0
|
作者：
Kristeleit, R. [1 ,2 ,3 ]
Calvert, H. [1 ,2 ,3 ]
Arkenau, H. [1 ,2 ,3 ]
Olmos, D. [1 ,2 ,3 ]
Adam, J. [1 ,2 ,3 ]
Plummer, E. R. [1 ,2 ,3 ]
Lock, V. [1 ,2 ,3 ]
Squires, M. [1 ,2 ,3 ]
Fazal, L. [1 ,2 ,3 ]
Judson, I. [1 ,2 ,3 ]
机构：
[1] No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[2] Royal Marsden Hosp, London SW3 6JJ, England
[3] Astex Therapeut Ltd, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2566
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia
    Foran, J. M.
    Ravandi, F.
    O'Brien, S. M.
    Borthakur, G.
    Rios, M.
    Boone, P.
    Worrell, J.
    Mallett, K. H.
    Squires, M.
    Fazal, L. H.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] A phase I trial of AT9283, a multitargeted kinase inhibitor in patients with refractory hematological malignancies
    Ravandi, Farhad
    Foran, James
    Verstovsek, Srdan
    Cortes, Jorge
    Wierda, William
    Boone, Patricia
    Borthukur, Gautam
    Sweeney, Trish
    Kantarjian, Hagop
    BLOOD, 2007, 110 (11) : 275A - 276A
  • [3] A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies
    Arkenau, H. -T.
    Plummer, R.
    Molife, L. R.
    Olmos, D.
    Yap, T. A.
    Squires, M.
    Lewis, S.
    Lock, V.
    Yule, M.
    Lyons, J.
    Calvert, H.
    Judson, I.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1307 - 1313
  • [4] A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study
    Moreno, Lucas
    Marshall, Lynley V.
    Pearson, Andrew D. J.
    Morland, Bruce
    Elliott, Martin
    Campbell-Hewson, Quentin
    Makin, Guy
    Halford, Sarah E. R.
    Acton, Gary
    Ross, Philip
    Kazmi-Stokes, Shamim
    Lock, Victoria
    Rodriguez, Ana
    Lyons, John F.
    Boddy, Alan V.
    Griffin, Melanie J.
    Yule, Murray
    Hargrave, Darren
    CLINICAL CANCER RESEARCH, 2015, 21 (02) : 267 - 273
  • [5] A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis
    Foran, James
    Ravandi, Farhad
    Wierda, William
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Kadia, Tapan
    Burger, Jan
    Yule, Murray
    Langford, Gillian
    Lyons, John
    Ayrton, John
    Lock, Victoria
    Borthakur, Gautham
    Cortes, Jorge
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (03): : 223 - 230
  • [6] A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191
    Hay, Annette E.
    Murugesan, Alli
    DiPasquale, Ashley M.
    Kouroukis, Tom
    Sandhu, Irwindeep
    Kukreti, Vishal
    Bahlis, Nizar J.
    Lategan, Johan
    Reece, Donna E.
    Lyons, John F.
    Sederias, Joana
    Xu, Hao
    Powers, Jean
    Seymour, Lesley K.
    Reiman, Tony
    LEUKEMIA & LYMPHOMA, 2016, 57 (06) : 1463 - 1466
  • [7] A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND. 191
    Hay, Annette E.
    Murugesan, Alli
    DiPasquale, Ashley M.
    Kouroukis, Tom
    Sandhu, Irwindeep
    Kukreti, Vishal
    Bahlis, Nizar J.
    Lategan, Johan
    Reece, Donna E.
    Lyons, John F.
    Sederias, Joana
    Powers, Jean
    Xu, Hao
    Seymour, Lesley K.
    Reiman, Anthony
    BLOOD, 2014, 124 (21)
  • [8] Aurora kinase inhibitor AT9283 potently inhibits the proliferation and migration of medulloblastoma cells
    Macdonald, Tobey J.
    Liu, Jingbo
    Lyons, John
    CANCER RESEARCH, 2011, 71
  • [9] A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia
    Vormoor, B.
    Veal, G. J.
    Griffin, M. J.
    Boddy, A. V.
    Irving, J.
    Minto, L.
    Case, M.
    Banerji, U.
    Swales, K. E.
    Tall, J. R.
    Moore, A. S.
    Toguchi, M.
    Acton, G.
    Dyer, K.
    Schwab, C.
    Harrison, C. J.
    Grainger, J. D.
    Lancaster, D.
    Kearns, P.
    Hargrave, D.
    Vormoor, J.
    PEDIATRIC BLOOD & CANCER, 2017, 64 (06)
  • [10] The Aurora kinase inhibitor AT9283 inhibits Burkitt lymphoma growth by regulating Warburg effect
    Jiang, Kaiming
    Bai, Lihong
    Wang, Canfei
    Xiao, Xiang
    Cheng, Zhao
    Peng, Hongling
    Liu, Sufang
    PEERJ, 2023, 11
12345